

Supplementary-material

Supplementary Table 1 Published research evaluating hepatitis B virus reactivation and resistance to antivirals in the past decade

	Title	Year	DOI
1	A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy	2016	10.1111/jgh.13231
2	Treatment of chronic hepatitis B	2006	https://www.cdc.gov/hepatitis-b/treatment/index.html
3	Evaluation of the risk of hepatitis B reactivation among patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	2016	10.1182/blood.V128.22.5429.5429
4	Current status of liver diseases in Korea: hepatitis B	2009	10.3350/kjhep.2009.15.S6.S13
5	The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice	2002	10.1046/j.1365-2893.2002.00385.x
6	Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation	2014	10.1016/j.jhep.2014.02.013
7	Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil	2006	PMID: 17310821
8	Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: A 4-year experience	2011	10.1111/j.1478-3231.2010.02416.x
9	On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective	2010	10.1111/j.1440-1746.2010.06271.x
10	Management of patients with hepatitis B in special populations	2015	10.3748/wjg.v21.i6.1738

11	Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B	2007	10.1016/j.antiviral.2007.02.003
12	Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics	2005	10.3748/wjg.v11.i28.4344
13	Management of hepatitis B	2004	10.1024/0040-5930.61.8.487
14	Lamivudine for the treatment of chronic hepatitis B	2000	PMID: 11233517
15	Management of chronic hepatitis B virus infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers	2003	10.5694/j.1326-5377.2003.tb05070.x
16	Management of drug-resistant chronic hepatitis B	2006	10.1016/j.cld.2006.05.004
17	Management of hepatitis B patients with antiviral resistance	2004	PMID: 15651760
18	Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B	2015	10.3748/wjg.v21.i27.8373
19	Treatment of chronic hepatitis B in HIV co-infected patients	2005	10.4061/2011/918017
20	The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients	2016	10.1111/jgh.13229
21	Chronic viral hepatitis: always be current	2003	10.1542/pir.24-12-399
22	Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain	2008	10.1097/MEG.0b013e3282f340c8
23	Introduction to chronic hepatitis type B	2004	PMID: 15453331
24	A multicenter study of the effectiveness of interferon alpha-1b (Hapgen) in treating HBeAg positive chronic hepatitis B patients	2011	10.3760/cma.j.issn.1007-3418.2011.01.008
25	High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a	2006	10.1007/s00535-005-1750-5

	lamivudine-resistant mutant: a prospective randomized controlled study		
26	Hepatitis and liver transplantation	2000	PMID: 20011084
27	Chronic hepatitis B virus infection in renal transplant recipients	2002	PMID: 12118403
28	Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection	2012	10.1007/s00535-011-0522-7
29	Does antiviral therapy prevent hepatocellular carcinoma?	2011	10.3851/imp1895
30	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy	2013	10.1002/hep.25937
31	Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B	2012	10.1097/MCG.0b013e318225f559
32	Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance	2005	10.1631/jzus.2005.B0664
33	De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis	2013	10.3748/wjg.v19.i37.6278
34	Prevention of hepatocellular carcinoma in hepatitis B virus infection	2009	10.1111/j.1440-1746.2009.05985.x
35	Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?	2011	10.1111/j.1440-1746.2010.06576.x
36	Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis	2013	10.1016/j.critrevonc.2012.12.004
37	Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C	2004	10.1111/j.1478-3231.2008.01696.x

- when treated with peginterferon alfa-2A (40KD)
(PEGASYS«) monotherapy
- 38 Evaluation of viral hepatitis in solid organ transplantation 2014 PMID: 26012153
- 39 Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study 1997 10.1053/gast.1997.v113.pm9322520
- 40 Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides 2009 10.1111/j.1365-2893.2009.01078.x
- 41 A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis 2008 10.1111/j.1440-1746.2007.05240.x
- 42 Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis 2009 10.1002/jmv.21348
- 43 Effect of long-term lamivudine in chronic hepatitis B virus-infected children 2004 PMID: 15535410
- 44 Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection 2004 PMID: 15040533
- 45 Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy 2015 10.1016/j.jhep.2015.01.002
- 46 Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study 2011 10.1136/gut.2010.221846

47	Hepatitis B and human immunodeficiency virus co-infection	2014	10.3748/wjg.v20.i46.17360
48	Treatment of hepatitis B in patients with chronic kidney disease	2013	10.1038/ki.2013.249
49	Liver transplantation for complications of hepatitis B	2006	10.1016/s0755-4982(06)74579-1
50	Non-interventional study AI463-12 of real-world chronic HBV infection management--baseline characteristics and treatment patterns of Polish patients cohort	2013	PMID: 24741906
51	Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B	2006	10.1002/hep.21020
52	Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review	2014	10.3748/wjg.v20.i40.14598
53	Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan	2003	10.1159/000071460
54	The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis	2012	10.1371/journal.pone.0032789
55	Benefits and risks of combination therapy for hepatitis B	2009	10.1002/hep.22921
56	[Therapy of hepatitis B]	2006	10.1024/1661-8157.95.36.1383
57	Hepatitis B virus infection and renal transplantation	2010	PMID: 20712048
58	Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis	2005	10.1111/j.1365-2893.2005.00608.x
59	Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: A long-term, prospective real-life study	2016	PMID: 27383049

60	Antiviral drugs for HBV liver disease	2011	10.1517/14712598.2011.546340
61	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy	2013	10.3748/wjg.v19.i47.8822
62	Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease	2009	10.1111/j.1440-1746.2009.05924.x
63	Introduction to chronic hepatitis B infection	2006	10.1111/j.1572-0241.2006.00469.x
64	A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period	2009	PMID: 19912686
65	Evolution of hepatitis B management in kidney transplantation	2014	10.3748/wjg.v20.i2.468
66	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy	2004	10.1200/jco.2004.05.161
67	The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis	2013	PMID: 23619252
